Videos

An interview with a phase 2 investigator on the the novel drug's potential in a field it wasn't originally designed to treat.

Experts discuss the prevalence and burden of sickle cell disease.

Wally Smith, MD, and Abdullah Kutlar, MD provide an overview of sickle cell disease and its pathophysiology.

Henry Nasrallah, MD, recalls the history behind long-acting injectables in patients with schizophrenia.

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, shares ways to improve naloxone accessibility, and Theresa Mallick-Searle, MS, RN-BC, ANP-BC, discusses stigmatization.

Experts weigh in on protocols, policies, and programs that influence patient safety and address when a conversation should ensue with patients about naloxone.

Linda Hemphill, MD, shares her views on how familial hypercholesterolemia impacts the assessment of high-risk patients.

Norman Lepor, MD, FACC, FAHA, FSCAI, shares how he would identify and monitor patient populations at high risk for CV morbidity and mortality.

An expert offers his perspective on the investigative SLP receptor modulator for atopic dermatitis.

The role of early aggressive treatment in preventing progression of heart failures and the importance of understanding the root cause of disease.

Javed Butler, MD, MPH, MBA, discusses the staging and difficulties associated with diagnosing heart failure.

An expert physician in cardiology and metabolic management walks through a presentation on identifying, addressing, and continually treating for heightened cardiometabolic risk.

A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.

Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.

Closing thoughts on advice to community pediatricians evaluating a baby for spinal muscular atrophy (SMA).

Several spinal muscular atrophy (SMA) resources are suggested to help physicians and families: Cure SMA, SMArt Moves, SMA Standard of Care documents, and the Child Neurology Foundation’s Telehealth Tip Sheet.

Experts suggest what to look for during a virtual examination during COVID-19 that may suggest a diagnosis of spinal muscular atrophy (SMA). If SMA is suspected, they stress the importance of an evaluation, as soon as possible, with a neurologist.

The workflow for a remote visit during COVID-19 is outlined.

Garey H. Noritz, MD, stresses the value of in-person office visits for babies to ensure they receive their vaccinations and physical examination.

Targeting early recognition of spinal muscular atrophy (SMA) and referral to a neurologist is emphasized.

On World TB Day, experts from the ALA and CDC reflect on the recent issues of tuberculosis.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.

Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.  

In commemoration of World TB Day, a CDC and ALA expert discuss how TB still exists in the country.

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regards to naloxone.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.

Expert panel of cardiologists provide their perspective on the specific population that may be at a risk of developing hyperlipidemia.